The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 21, 2014

Filed:

Oct. 31, 2009
Applicant:

Mitchell S. Felder, Hermitage, PA (US);

Inventor:

Mitchell S. Felder, Hermitage, PA (US);

Assignee:

Altman Enterprises, LLC, El Paso, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/44 (2006.01); A61K 31/12 (2006.01); A61K 31/70 (2006.01); A61K 31/435 (2006.01); A61K 31/135 (2006.01); A61K 31/4415 (2006.01); A61K 31/585 (2006.01); A61K 31/122 (2006.01); A61K 31/714 (2006.01);
U.S. Cl.
CPC ...
A61K 31/122 (2013.01); A61K 31/4415 (2013.01); A61K 31/585 (2013.01); A61K 31/714 (2013.01);
Abstract

A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 μg vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.


Find Patent Forward Citations

Loading…